Back to top
more

Hemispherx BioPharma, Inc. (AIM)

(Delayed Data from AMEX)

$2.01 USD

2.01
795,334

-0.08 (-3.83%)

Updated Oct 28, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.53%
2Buy17.99%
3Hold9.63%
4Sell5.14%
5Strong Sell2.00%
S&P50010.72%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (165 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida.

General Information

Hemispherx BioPharma Inc

2117 SW HIGHWAY 484

OCALA, FL 34473

Phone: 352-448-7797

Fax: 215-988-1739

Web: NA

Email: ir@aimimmuno.com

Industry Medical - Drugs
Sector Medical
Fiscal Year End December
Last Reported Quarter 9/30/2020
Next EPS Date NA

EPS Information

Current Quarter EPS Consensus Estimate NA
Current Year EPS Consensus Estimate NA
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date NA

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 2.09
52 Week High 7.11
52 Week Low 0.38
Beta -0.98
20 Day Moving Average 1,095,916.00
Target Price Consensus 5.00

AIM

% Price Change
4 Week -1.42
12 Week -25.09
YTD 284.19
% Price Change Relative to S&P 500
4 Week -3.02
12 Week -26.95
YTD 263.22
Share Information
Shares Outstanding (millions) 39.69
Market Capitalization (millions) 82.95
Short Ratio NA
Last Split Date 6/11/2019
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 89.72%
vs. Previous Quarter 50.00%
   
Sales Growth
vs. Previous Year 37.93%
vs. Previous Quarter -11.11%
   
Price Ratios
Price/Book 1.47
Price/Cash Flow NA
Price / Sales 423.22
ROE
9/30/20 NA
6/30/20 -42.76
3/31/20 -61.48
ROA
9/30/20 NA
6/30/20 -33.45
3/31/20 -40.31
Current Ratio
9/30/20 NA
6/30/20 42.22
3/31/20 42.26
Quick Ratio
9/30/20 NA
6/30/20 42.21
3/31/20 42.26
Operating Margin
9/30/20 NA
6/30/20 -5,770.41
3/31/20 -5,388.65
Net Margin
9/30/20 NA
6/30/20 -5,770.41
3/31/20 -5,388.65
Pre-Tax Margin
9/30/20 NA
6/30/20 -5,770.41
3/31/20 -5,392.43
Book Value
9/30/20 NA
6/30/20 1.42
3/31/20 1.24
Inventory Turnover
9/30/20 NA
6/30/20 NA
3/31/20 NA
Debt-to-Equity
9/30/20 NA
6/30/20 0.04
3/31/20 0.18
Debt to Capital
9/30/20 NA
6/30/20 4.07
3/31/20 15.11